B.More Collaborator Receives Grant to Study Psilocybin-Assisted Treatment for Alcohol-Use Disorder October 12, 2024
NRx Pharmaceuticals Completes 12 Months of Stability on First Commercial-Scale Lot of IV Ketamine September 30, 2024
Microdosing Collective: Diamond Shruumz Recall ‘Tragically Highlights’ Risks of ‘Black-Market’ Psychedelics August 26, 2024
Johnson & Johnson Seeks FDA Approval of Spravato as Monotherapy for Adults with Treatment-Resistant Depression
